Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1990 1
1995 1
1997 1
2002 2
2003 2
2007 1
2008 1
2009 1
2010 1
2011 1
2012 3
2013 1
2014 3
2015 1
2016 2
2018 3
2019 3
2020 2
2021 4
2022 1
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Treosulfan-based conditioning for inborn errors of immunity.
Slatter MA, Gennery AR. Slatter MA, et al. Ther Adv Hematol. 2021 May 20;12:20406207211013985. doi: 10.1177/20406207211013985. eCollection 2021. Ther Adv Hematol. 2021. PMID: 34094045 Free PMC article. Review.
It is firmly incorporated into the conditioning guidelines of the Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation. Unlike busulfan, pharmacokinetically guided dosing of treosulfan is not part of routine practice, but data are emergi …
It is firmly incorporated into the conditioning guidelines of the Inborn Errors Working Party of the European Society for Blood and Marrow T …
Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives.
Romański M, Wachowiak J, Główka FK. Romański M, et al. Clin Pharmacokinet. 2018 Oct;57(10):1255-1265. doi: 10.1007/s40262-018-0647-4. Clin Pharmacokinet. 2018. PMID: 29557088 Free PMC article. Review.
Furthermore, the organ disposition of treosulfan and S,S-EBDM in rats is discussed in the context of the clinical toxicity and myeloablative activity of treosulfan versus busulfan. Moreover, perspectives for future therapeutic drug monitoring of treosulfan ar …
Furthermore, the organ disposition of treosulfan and S,S-EBDM in rats is discussed in the context of the clinical toxicity and myeloa …
Treosulfan Versus Busulfan-based Conditioning in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis.
Wu W, Xue N, Yang H, Gao P, Guo J, Han D. Wu W, et al. J Pediatr Hematol Oncol. 2023 Oct 1;45(7):370-376. doi: 10.1097/MPH.0000000000002735. Epub 2023 Jul 26. J Pediatr Hematol Oncol. 2023. PMID: 37526377
It is unclear whether there is a difference in outcomes with treosulfan or busulfan-based conditioning in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT). ...Retrospective data from a heterogenous population indicates that there is no differenc …
It is unclear whether there is a difference in outcomes with treosulfan or busulfan-based conditioning in pediatric patients undergoi …
Treosulfan (Trecondyv): CADTH Reimbursement Recommendation: Indication: Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia or myelodysplastic syndromes at increased risk for standard conditioning therapies.
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar. Report No.: PC0324. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar. Report No.: PC0324. PMID: 38648307 Free Books & Documents. Review.
Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics.
ten Brink MH, Zwaveling J, Swen JJ, Bredius RG, Lankester AC, Guchelaar HJ. ten Brink MH, et al. Drug Discov Today. 2014 Oct;19(10):1572-86. doi: 10.1016/j.drudis.2014.04.005. Epub 2014 Apr 16. Drug Discov Today. 2014. PMID: 24747172 Review.
Busulfan- and treosulfan-based conditionings are the cornerstone of pediatric allogeneic hematopoietic stem cell transplantation (HSCT). ...However, knowledge of the PK and PG of treosulfan is limited. In this review, we describe the pharmacology of both agents and …
Busulfan- and treosulfan-based conditionings are the cornerstone of pediatric allogeneic hematopoietic stem cell transplantation (HSC …
Clinical bioanalysis of treosulfan and its epoxides: The importance of collected blood processing for valid pharmacokinetic results.
Romański M, Główka F. Romański M, et al. J Pharm Biomed Anal. 2018 May 10;153:199-203. doi: 10.1016/j.jpba.2018.02.049. Epub 2018 Feb 24. J Pharm Biomed Anal. 2018. PMID: 29501039 Review.
For that purpose, pharmacokinetic analyses are ongoing within clinical phase II and III trials. In this paper, HPLC methods for determination of prodrug treosulfan and/or its biologically active epoxides in human plasma or serum are reviewed for the first time, including t …
For that purpose, pharmacokinetic analyses are ongoing within clinical phase II and III trials. In this paper, HPLC methods for determinatio …
Long-Term Outcomes of Treosulfan- vs. Busulfan-Based Conditioning Regimen for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia Before Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
Zhu S, Liu G, Liu J, Chen Q, Wang Z. Zhu S, et al. Front Oncol. 2020 Dec 16;10:591363. doi: 10.3389/fonc.2020.591363. eCollection 2020. Front Oncol. 2020. PMID: 33425740 Free PMC article.
BACKGROUND: Many studies aimed to evaluate the efficacy and safety of treosulfan-based conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT) compared with other regimens, but different outcomes were reported across studies. AIM: To determine th …
BACKGROUND: Many studies aimed to evaluate the efficacy and safety of treosulfan-based conditioning regimens for allogeneic hematopoi …
An International Survey of Allogeneic Hematopoietic Cell Transplantation for X-Linked Agammaglobulinemia.
Nishimura A, Uppuluri R, Raj R, Swaminathan VV, Cheng Y, Abu-Arja RF, Fu B, Laberko A, Albert MH, Hauck F, Bucciol G, Bigley V, Elcombe S, Kharya G, Pronk CJH, Wehr C, Neven B, Warnatz K, Meyts I, Morio T, Gennery AR, Kanegane H. Nishimura A, et al. J Clin Immunol. 2023 Nov;43(8):1827-1839. doi: 10.1007/s10875-023-01551-2. Epub 2023 Jul 16. J Clin Immunol. 2023. PMID: 37454339 Review.
In all patients, 2-year overall survival (OS) and event-free survival (EFS) were 86% and 77%, respectively. In patients who received RT-MAC or RIC using treosulfan, busulfan, or melphalan, 2-year OS and EFS were 82% and 71%, respectively. ...
In all patients, 2-year overall survival (OS) and event-free survival (EFS) were 86% and 77%, respectively. In patients who received RT-MAC …
24 results